The interaction between HA and its receptor CD44, together with the excellent HA biocompatibility, biodegradability, and nonimmunogenicity, has also been exploited to increase the delivery of conventional antineoplastic drugs into tumor cells. The gene discussed is CD44; the disease is neoplasm.